Amgen touts two cancer study wins with DLL3, Lumakras amid second-quarter earnings update
03 Aug 2023
Phase 1Phase 2Clinical ResultClinical Trial FailureFinancial Statement
Two cancer drugs succeeded in mid- or late-stage clinical studies, Amgen said Thursday in its second-quarter earnings announcement.
“Momentum is building in the pipeline,” Amgen CFO Peter Griffith told
Endpoints News
, adding the biotech plans to discuss both datasets with regulators, calling a study for the DLL3-targeting drug tarlatamab “potentially registrational.”
In a Phase II small cell lung cancer study, tarlatamab showed a durable response rate that “substantially exceeds what was previously reported in the Phase I study,” the $123 billion drugmaking giant said in its midyear update. But specific data were sparse in Thursday’s release; Amgen said it will present more detailed results at an upcoming medical conference.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.